Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. announced that PharmAla has completed the first sale of a quantity of Mindset's cGMP (i.e. pharmaceutical grade) psilocybin under their exclusive sales agreement. The psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX listed Little Green Pharma. Reset recently received human research ethics committee approval for a clinical trial investigating psilocybin assisted psychotherapy protocols for patients with treatment resistant major depressive disorder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 CAD | 0.00% | -7.32% | +35.71% |
May. 03 | PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy | MT |
Apr. 23 | Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla | CI |
1st Jan change | Capi. | |
---|---|---|
+35.71% | 12.09M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. Complete First Sale of Pharmaceutical Grade Psilocybin into Growing Australian Market Via Sales Partnership